 |
|
|
| |
New HIV & HCV Drugs at IAS / Dual ARTs / Fatty Liver in HIV+
|
| |
| |
100 IAS Reports: IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention
Paris, France - July 23-26 2017
IAS: LONG-ACTING IBALIZUMAB SUSCEPTIBILITY IN MULTI-DRUG RESISTANT HIV PATIENTS - (10/12/17)
IAS: Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxilfumarate regimens to the single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults through 24 weeks: EMERALD Study - (07/25/17)
IAS: Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)
IAS: Sub-Study 202094 of SWORD-1 and SWORD-2: Switch From TDF-Containing Regimen to DTG + RPV Improves Bone Mineral Density and Bone Turnover Markers Over 48 Weeks - (07/26/17)
IAS: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
IAS: Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17)
IAS: Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96 - (07/24/17)
IAS: A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17)
IAS: Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results - (07/27/17)
IAS: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/23/17)
IAS: Fixed-Dose Combination of Doravirine/Lamivudine/TDF is Non-Inferior to Efavirenz/Emtricitabine/TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study - (07/25/17)
IAS: Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection - (07/25/17)
IAS: Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
IAS: Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17)
IAS: MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing - (07/23/17)
IAS: Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study - (07/25/17)
IAS: Evaluation of lead HIV-1 vaccine regimen in APPROACH: Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein - (07/24/17)
IAS: ABX464 decreases total HIV DNA in PBMC's when administered during 28 days to HIV-infected patients who are virologically suppressed - (07/28/17)
IAS: ANRS 146 - GeSIDA 7211 OPTIMAL Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts > 200 cells/ mm3 - (07/24/17)
IAS: More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex -
(07/23/17)
more Dual ARTs
IAS: Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial - (07/27/17)
IAS: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - (07/31/17)
IAS: Darunavir/Ritonavir Plus 3TC Noninferior to Triple Therapy at 24 Weeks - ANDES Study - A Phase 4, Randomized, Open Label, Study of a Ritonavir-Boosted Darunavir in Fixed Dose Combination (FD-DRV/r) plus Lamivudine Versus FD-DRV/r plus Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects - - (07/23/17)
IAS: Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial - (07/25/17)
Dual ART Therapy Regimens - (07/23/17)
IAS: New HIV Drugs, Aging, Life Expectancy - (07/26/17)
Fatty Liver in HIV+ at IAS
IAS: Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study - (07/25/17)
IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
IAS: Fatty Liver in HIV+ at IAS- (08/05/17)
Current and Future Therapeutic Approaches to NAFLD/NASH - (08/05/17)
Hepatitis C
IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17)
IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17)
Gilead Vosevi FDA PI, Package Insert / Label - (08/06/17)
FDA - G/P - Trials, Package Insert, MAVYRET approved to treat HCV - (08/05/17)
European Commission Grants Marketing Authorization for Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C - (07/28/17)
European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) - (07/28/17)
|
| |
|
|
|
|
|
